Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Can Aspirin Reduce the Risk of Hepatocellular Carcinoma (HCC) in Participants With Cirrhosis: a Multicentre, Placebo-controlled Clinical Trial - The AspiRe HCC Trial

NCT07529262 is registered in ClinicalTrials.gov with Curtin University as lead sponsor.

NCT NCT07529262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07529262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Can Aspirin Reduce the Risk of Hepatocellular Carcinoma (HCC) in Participants With Cirrhosis: a Multicentre, Placebo-controlled Clinical Trial - The AspiRe HCC Trial
Lead sponsor
Curtin University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
June 30, 2030
Enrollment
890 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhosis